Investing.com - Oramed reported on Wednesday fourth quarter earnings that beat analysts' forecasts and revenue that fell short of expectations.
Oramed announced earnings per share of $-0.18 on revenue of $700K. Analysts polled by Investing.com anticipated EPS of $-0.19 on revenue of $1.26M.
Oramed shares are down 50.68% from the beginning of the year, still down 58.02% from its 52 week high of $6.05 set on December 19, 2019. They are under-performing the Nasdaq which is up 24.66% from the start of the year.
Oramed follows other major Healthcare sector earnings this month
Oramed's report follows an earnings beat by J&J on October 13, who reported EPS of $2.2 on revenue of $21.08B, compared to forecasts EPS of $1.98 on revenue of $20.2B.
Pfizer had beat expectations on Tuesday with third quarter EPS of $0.72 on revenue of $12.13B, compared to forecast for EPS of $0.69 on revenue of $12.31B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar